Eli Lilly's quarterly financial reports

FDA Approves Eli Lilly's EBGLYSS™ Eczema Drug for Adults and Children on Friday

Sep 13, 2024, 11:10 PM

Eli Lilly announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its eczema drug, EBGLYSS™ (lebrikizumab-lbkz), for use in adults and children aged 12 years and older. The drug is intended to treat moderate-to-severe atopic dermatitis, a condition characterized by itchy, dry, and scaly skin. This approval marks a significant advancement for individuals suffering from eczema, offering a new treatment option for a diverse group of patients.